For Monotherapy, P2Y12 Inhibitor Bests Aspirin After PCI for ACS: Meta-analysis
The study can’t supplant an RCT in this space, but does provide clear support for both short DAPT and P2Y12 inhibitors post-ACS.
The study can’t supplant an RCT in this space, but does provide clear support for both short DAPT and P2Y12 inhibitors post-ACS.
ATTAIN-1 is the second trial this year to show positive results with once-daily orforglipron, with best results seen at the top dose.
Yet 44% of the high-risk patients, from LAAO’s early era, died by 5 years—researchers say this knowledge can aid decision-making.
Gilbert Tang, MD Mount Sinai Health System New York, NY Firas Zahr, MD Oregon Health & Science University Portland, OR Forgot Your Password? Enter the…
The document, last updated in 2017, promotes use of the PREVENT calculator as well as more flexible BP goals.
Mamas Mamas sits down with Sergio Dominguez Miranda for an overview on the use of digital twins to predict patient outcomes.
Effects are more modest in placebo-controlled versus nonrandomized studies, with experts calling for further research.
The document, last updated in 2017, promotes use of the PREVENT calculator as well as more flexible BP goals.
The drug could be an option for patients who are unable to tolerate statins, or unwilling to take them.
Continuing the conversation, Juan Granada hears about Guido Ascione’s recent presentation on the global burden of degenerative mitral valve disease at NY Valves 2025.
Rebecca Hahn, MD Columbia University Irving Medical Center New York, NY Alison Duncan, MBBS, PhD Royal Brompton Hospital London, England Forgot Your Password? Enter the…